Immunogenicity of chimeric haemagglutinin-based,universal influenza virus vaccine candidates: interim results of a randomised,placebo-controlled,phase 1 clinical trial |
| |
| Affiliation: | 1. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA;2. Division of Infectious Diseases, Cincinnati Children''s Hospital Medical Center, Cincinnati, OH, USA;3. Duke Early Phase Clinical Research Unit, Duke Clinical Research Institute, Durham, NC, USA;4. Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA;5. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA;6. Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA;8. Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, USA;9. The Committee on Immunology, University of Chicago, Chicago, IL, USA;10. GlaxoSmithKline, Wavre, Belgium;11. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA;12. GlaxoSmithKline, Collegeville, PA, USA;13. Department of Microbiology and Plant Pathology, Institute for Integrative Genome Biology, University of California, Riverside, CA, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
